Skip to content
DataLookout
Menu

ASCENDNCT07935135

Study of CMP-002 in Participants With SYNGAP1-Related Disorder

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and tolerability of multiple doses of CMP-002: incidence of adverse events and changes from baseline in clinical laboratory results
Timeframe: Screening to Week 36

Secondary (5)

CSF concentrations of the active drug substance of CMP-002 after multiple doses
Plasma PK of the active drug substance of CMP-002 after multiple doses: Cmax
Plasma PK of the active drug substance of CMP-002 after multiple doses: AUC(0-24h)
Urine PK of the active drug substance of CMP-002: Cmax
Urine PK of the active drug substance of CMP-002: AUC(0-24hr)

Arms and interventions

CMP-002 Multiple Ascending Dose (MAD)Experimental

Participants will be administered CMP-002 on Days 1, 29, and 85, and will be followed for 24 weeks after the last dose. Three dose levels will be evaluated.

Sham-prickSham comparator

Participants will receive the sham-prick procedure on Days 1, 29, and 85, and will be followed for 24 weeks after the last procedure.

Drugs: CMP-002

Other: Sham-prick

Sites

1 site in 1 country

  • Hospital AlemánBuenos Aires, Argentina